Sökning: WFRF:(Dietz R)
> (2005-2009) >
Resource utilizatio...
Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme
-
McMurray, J. J. (författare)
-
Andersson, F. L. (författare)
-
Stewart, S. (författare)
-
visa fler...
-
Svensson, K. (författare)
-
Solal, A. C. (författare)
-
Dietz, R. (författare)
-
Vanhaecke, J. (författare)
-
van Veldhuisen, D. J. (författare)
-
- Ostergren, J. (författare)
- Karolinska Institutet
-
Granger, C. B. (författare)
-
Yusuf, S. (författare)
-
Pfeffer, M. A. (författare)
-
- Swedberg, Karl, 1944 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för akut och kardiovaskulär medicin,Institute of Medicine, Department of Emergeny and Cardiovascular Medicine
-
visa färre...
-
(creator_code:org_t)
- 2005-10-24
- 2006
- Engelska.
-
Ingår i: European heart journal. - : Oxford University Press (OUP). - 0195-668X .- 1522-9645. ; 27:12, s. 1447-58
- Relaterad länk:
-
https://academic.oup...
-
visa fler...
-
https://gup.ub.gu.se...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- AIMS: More treatments are needed to improve clinical outcomes in chronic heart failure (HF). It is, however, important that treatments for a condition as common as HF are affordable. We have carried out a prospective economic analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. METHODS AND RESULTS: Patients with NYHA class II-IV HF and LVEF < or =0.40 were randomized to CHARM-Alternative if intolerant of an ACE-inhibitor or to CHARM-Added if taking an ACE-inhibitor. Patients with a LVEF >0.40 were randomized in CHARM-Preserved. Each trial compared the effect of candesartan to placebo on the primary outcome of cardiovascular death or HF hospitalization. Detailed information was prospectively collected on hospital admissions, procedures/operations and drugs. A cost-consequence analysis was performed for France, Germany and the UK for CHARM-Overall and a cost-effectiveness analysis for the low LVEF trials. The cost of candesartan was substantially offset by a reduction in hospital admissions, especially for HF. In the cost-consequence analysis, candesartan was cost-saving in most scenarios for CHARM-Alternative and Added but the marginal annual net cost per patient was upto 372 euros per year in CHARM-Preserved, in which candesartan did not reduce the primary outcome significantly. In the cost-effectiveness analysis of patients with a LVEF < or = 0.40, candesartan was cost-saving in some scenarios and in the others the maximum cost per life year gained was 3881 euros. CONCLUSION: Candesartan improves functional class, reduces the risk of hospital admission, and increases survival in patients with a HF and a LVEF < or =0.40 at an acceptable cost.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kardiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)
Nyckelord
- Angiotensin II Type 1 Receptor Blockers/*economics/therapeutic use
- Benzimidazoles/*economics/therapeutic use
- Cardiac Pacing
- Artificial/statistics & numerical data
- Cost-Benefit Analysis
- Drug Costs
- Heart Failure
- Congestive/*drug therapy/economics/mortality
- Hospital Costs
- Hospitalization/statistics & numerical data
- Humans
- Risk Factors
- Survival Analysis
- Tetrazoles/*economics/therapeutic use
- Thoracic Surgical Procedures/statistics & numerical data
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
McMurray, J. J.
-
Andersson, F. L.
-
Stewart, S.
-
Svensson, K.
-
Solal, A. C.
-
Dietz, R.
-
visa fler...
-
Vanhaecke, J.
-
van Veldhuisen, ...
-
Ostergren, J.
-
Granger, C. B.
-
Yusuf, S.
-
Pfeffer, M. A.
-
Swedberg, Karl, ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Kardiologi
- Artiklar i publikationen
-
European heart j ...
- Av lärosätet
-
Göteborgs universitet
-
Karolinska Institutet